Breast cancer resistance to CDK4/6 inhibitors arises in many ways
Breast cancer cells became resistant to therapeutics targeting CDK4/6, such as palbociclib (Ibrance), in multiple ways, and preclinical studies suggested different combinations of therapeutics may prevent and overcome the ...
Mar 28, 2016
0
6